Three organisations have been shortlisted for the inaugural Drug Development Innovation award.
Part of the Health Tech World Awards, it recognoses scientific excellence across all stages of drug discovery, from identifying promising molecular targets to delivering novel drugs that improve patient outcomes.
The award is sponsored by Kisaco Research.
Kisaco Research produces, designs and hosts B2B industry conference and exhibitions.
The company works with the early adopters and leaders of growth markets in driving their respective industries forward and in providing the right knowledge, learning and social opportunities to stimulate business growth quickly and effectively.
A winner from the shortlist will be chosen by the sponsor and announced at a virtual ceremony on May 8.
Congratulations to the shortlisted organisations and thank you to everyone who entered.
Drug Development Innovation Shortlist
Our proprietary platform seamlessly integrates the massive data-processing power of LLMs with cutting-edge immune repertoire analysis techniques.
This powerful combination allows researchers and clinicians to identify novel biomarkers, accurately predict therapeutic outcomes, and craft potent treatment strategies.
Through our relentless commitment to innovation and excellence, Etcembly is leading the charge in next-generation immunotherapy, with the ultimate goal of transforming patient care for a cancer-free future.
About to celebrate four years of advanced research and development, SynaptixBio is a rare disease biotech pioneering ground-breaking therapies for the treatment of severe leukodystrophies.
In its journey so far, the company has raised over £13 million to fund research and preclinical development, gained all necessary approvals from the FDA, and is now very close to selecting a candidate drug for clinical trials.
Oxford-based SynaptixBio entered into a licensing agreement in 2022 with the Children’s Hospital of Philadelphia (CHOP), the world’s leading leukodystrophy research centre, to develop a therapeutic for H-ABC, the most severe form of TUBB4A related leukodystrophy.
Researchers from the University of Cincinnati College of Medicine and Cincinnati Children’s Hospital have found a new method to increase both speed and success rates in drug discovery.
The approach offers renewed promise when it comes to discovering new drugs.
Researchers combined two approaches for screening potential new drugs.
First, they used a database from the Library of Integrated Network-based Cellular Signatures (LINCS) to screen tens of thousands of small molecules with potential therapeutic effects simultaneously.
Then they combined the search with targeted docking simulations used to model the interaction between small molecules and their protein targets to find compounds of interest.
That sped up the timing of the work from months to minutes — taking weeks of work required for initial screening down to an afternoon.
